Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 8, 2015, Pages 1037-1050

  Bellini, Lara ^a   Campana, Melanie ^a   Mahfouz, Rana ^a,b,c   Carlier, Aurelie ^a,b,c   Veret, Julien ^a   Magnan, Christophe ^a   Hajduch, Eric ^a,b,c   Le Stunff, Herve ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Adipose tissue; apoptosis; ceramide; insulin; islet of Langerhans; lipotoxicity; liver; muscle; obesity; pancreatic b cells; sphingolipids; sphingosine 1 phosphate; type 2 diabetes

Indexed keywords

APOLIPOPROTEIN B; CERAMIDE; GLUCOSE; INSULIN; PHOSPHATE; PROTEIN KINASE B; PROTEIN KINASE R; SERINE PALMITOYLTRANSFERASE; SPHINGANINE; SPHINGOID BASE PHOSPHATE; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; UNCLASSIFIED DRUG; FATTY ACID;

ADIPOCYTE; ADIPOSE TISSUE; APOPTOSIS; B LYMPHOCYTE; CARBOHYDRATE METABOLISM; CELL ACTIVITY; CELL FUNCTION; CELL STRESS; CELLULAR DISTRIBUTION; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM; GLUCOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCOLYSIS; HUMAN; HYPOTHALAMUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIPID STORAGE; LIPOGENESIS; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PROTEIN DEPHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SKELETAL MUSCLE; SPHINGOLIPID METABOLISM; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CERAMIDES; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; HUMANS; INSULIN RESISTANCE; OBESITY; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 84937139245     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1028359     Document Type: Review

References (102)

1. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med 2006;12(1):75-80
2. Flamment M, Hajduch E, Ferre P, et al. New insights into ER stress-induced insulin resistance. Trends Endocrinol Metab 2012;23(8):381-90
3. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012;148(5):852-71
4. Carey DG, Jenkins AB, Campbell LV, et al. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996;45(5):633-8
5. Paolisso G, Gambardella A, Amato L, et al. Opposite effects of short-and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 1995;38(11):1295-9
6. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1(7285):785-9
7. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996;97(12):2859-65
8. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008;29(3):351-66
9. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002;32(Suppl 3):14-23
10. Cowart LA. Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol Metab 2009;20(1):34-42
11. Ussher JR, Koves TR, Cadete VJ, et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 2010;59(10):2453-64
12. Mullen TD, Hannun YA, Obeid LM. Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem J 2012;441(3):789-802
13. Hanada K, Kumagai K, Yasuda S, et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature 2003;426(6968):803-9
14. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9(2):139-50
15. Adams JM II, Pratipanawatr T, Berria R, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004;53(1):25-31
16. Coen PM, Dube JJ, Amati F, et al. Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content. Diabetes 2010;59(1):80-8
17. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008;29(4):381-402
18. Hage Hassan R, Bourron O, Hajduch E. Defect of insulin signal in peripheral tissues: important role of ceramide. World J Diabetes 2014;5(3):244-57
19. Mahfouz R, Khoury R, Blachnio-Zabielska A, et al. Characterising the inhibitory actions of ceramide upon insulin signaling in different skeletal muscle cell models: a mechanistic insight. PLoS One 2014;9(7):e101865
20. Chavez JA, Summers SA. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 2003;419(2):101-9
21. Hajduch E, Balendran A, Batty IH, et al. Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 2001;44(2):173-83
22. Nordby P, Prats C, Kristensen D, et al. Muscle ceramide content in man is higher in type I than type II fibers and not influenced by glycogen content. Eur J Appl Physiol 2010;109(5):935-43
23. Asmann YW, Stump CS, Short KR, et al. Skeletal muscle mitochondrial functions, mitochondrial DNA copy numbers, and gene transcript profiles in type 2 diabetic and nondiabetic subjects at equal levels of low or high insulin and euglycemia. Diabetes 2006;55(12):3309-19
24. Cazzolli R, Carpenter L, Biden TJ, et al. A role for protein phosphatase 2A-like activity, but not atypical protein kinase Czeta, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes 2001;50(10):2210-18
25. Turban S, Hajduch E. Protein kinase C isoforms: mediators of reactive lipid metabolites in the development of insulin resistance. FEBS Lett 2011;585(2):269-74
26. Powell DJ, Hajduch E, Kular G, et al. Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 2003;23(21):7794-808
27. Hajduch E, Turban S, Le Liepvre X, et al. Targeting of PKCzeta and PKB to caveolin-enriched microdomains represents a crucial step underpinning the disruption in PKB-directed signalling by ceramide. Biochem J 2008;410(2):369-79
28. Farese RV, Lee MC, Sajan MP. Atypical PKC: a target for treating insulinresistant disorders of obesity, the metabolic syndrome and type 2 diabetes mellitus. Expert Opin Ther Targets 2014;18(10):1163-75
29. Fox TE, Houck KL, O'Neill SM, et al. Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J Biol Chem 2007;282(17):12450-7
30. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387(6633):569-72
31. Oka N, Yamamoto M, Schwencke C, et al. Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem 1997;272(52):33416-21
32. Blouin CM, Prado C, Takane KK, et al. Plasma membrane subdomain compartmentalization contributes to distinct mechanisms of ceramide action on insulin signaling. Diabetes 2010;59(3):600-10
33. Yamaguchi M, Miyashita Y, Kumagai Y, et al. Change in liver and plasma ceramides during D-galactosamine-induced acute hepatic injury by LC-MS/MS. Bioorg Med Chem Lett 2004;14(15):4061-4
34. Monetti M, Levin MC, Watt MJ, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007;6(1):69-78
35. Holland WL, Bikman BT, Wang LP, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest 2011;121(5):1858-70
36. Yang G, Badeanlou L, Bielawski J, et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009;297(1):E211-24
37. Kurek K, Piotrowska DM, Wiesiolek-Kurek P, et al. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int 2013;34(7):1074-83
38. Turpin SM, Nicholls HT, Willmes DM, et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab 2014;20(4):678-86
39. Raichur S, Wang ST, Chan PW, et al. CerS2 haploinsufficiency inhibits betaoxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab 2014;20(4):687-95
40. Merrill AH Jr, Lingrell S, Wang E, et al. Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion. J Biol Chem 1995;270(23):13834-41
41. Boon J, Hoy AJ, Stark R, et al. Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes 2013;62(2):401-10
42. Sajan MP, Acevedo-Duncan ME, Standaert ML, et al. Akt-dependent phosphorylation of hepatic FoxO1 is compartmentalized on a WD40/ProF scaffold and is selectively inhibited by aPKC in early phases of diet-induced obesity. Diabetes 2014;63(8):2690-701
43. Friedman RM, Metz DH, Esteban RM, et al. Mechanism of interferon action: inhibition of viral messenger ribonucleic acid translation in L-cell extracts. J Virol 1972;10(6):1184-98
44. Dabo S, Meurs EF. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses 2012;4(11):2598-635
45. Carvalho BM, Oliveira AG, Ueno M, et al. Modulation of double-stranded RNA-activated protein kinase in insulin sensitive tissues of obese humans. Obesity (Silver Spring) 2013;21(12):2452-7
46. Yang X, Nath A, Opperman MJ, et al. The double-stranded RNA-dependent protein kinase differentially regulates insulin receptor substrates 1 and 2 in HepG2 cells. Mol Biol Cell 2010;21(19):3449-58
47. Nakamura T, Arduini A, Baccaro B, et al. Small-molecule inhibitors of PKR improve glucose homeostasis in obese diabetic mice. Diabetes 2014;63(2):526-34
48. Kolak M, Westerbacka J, Velagapudi VR, et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007;56(8):1960-8
49. Shah C, Yang G, Lee I, et al. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 2008;283(20):13538-48
50. Long SD, Pekala PH. Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J 1996;319(Pt 1):179-84
51. Barbarroja N, Rodriguez-Cuenca S, Nygren H, et al. Increased dihydroceramide/ceramide ratio mediated by defective expression of degs1 impairs adipocyte differentiation and function. Diabetes 2014. [Epub ahead of print].
52. Veluthakal R, Palanivel R, Zhao Y, et al. Ceramide induces mitochondrial abnormalities in insulin-secreting INS-1 cells: potential mechanisms underlying ceramide-mediated metabolic dysfunction of the beta cell. Apoptosis 2005;10(4):841-50
53. Veret J, Coant N, Berdyshev EV, et al. Ceramide synthase 4 and de novo production of ceramides with specific N-acyl chain lengths are involved in glucolipotoxicity-induced apoptosis of INS-1 beta-cells. Biochem J 2011;438(1):177-89
54. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001;15(2):312-21
55. Kogot-Levin A, Saada A. Ceramide and the mitochondrial respiratory chain. Biochimie 2014;100:88-94
56. Lang F, Ullrich S, Gulbins E. Ceramide formation as a target in beta-cell survival and function. Expert Opin Ther Targets 2011;15(9):1061-71
57. Laybutt DR, Preston AM, Akerfeldt MC, et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 2007;50(4):752-63
58. Boslem E, MacIntosh G, Preston AM, et al. A lipidomic screen of palmitatetreated MIN6 beta-cells links sphingolipid metabolites with endoplasmic reticulum (ER) stress and impaired protein trafficking. Biochem J 2011;435(1):267-76
59. Park JW, Park WJ, Kuperman Y, et al. Ablation of very long acyl chain sphingolipids causes hepatic insulin resistance in mice due to altered detergent-resistant membranes. Hepatology 2013;57(2):525-32
60. Gjoni E, Brioschi L, Cinque A, et al. Glucolipotoxicity Impairs Ceramide Flow from the Endoplasmic Reticulum to the Golgi Apparatus in INS-1 beta-Cells. PLoS One 2014;9(10):e110875
61. Riboni L, Giussani P, Viani P. Sphingolipid transport. Adv Exp Med Biol 2010;688:24-45
62. Kelpe CL, Moore PC, Parazzoli SD, et al. Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis. J Biol Chem 2003;278(32):30015-21
63. Hagman DK, Hays LB, Parazzoli SD, et al. Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans. J Biol Chem 2005;280(37):32413-18
64. Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J 1998;335(Pt 3):465-80
65. Kaneto H, Xu G, Fujii N, et al. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 2002;277(33):30010-18
66. Guo J, Qian Y, Xi X, et al. Blockage of ceramide metabolism exacerbates palmitate inhibition of pro-insulin gene expression in pancreatic beta-cells. Mol Cell Biochem 2010;338(1-2):283-90
67. Guo J, Zhu JX, Deng XH, et al. Palmitate-induced inhibition of insulin gene expression in rat islet beta-cells involves the ceramide transport protein. Cell Physiol Biochem 2010;26(4-5):717-28
68. Yano M, Watanabe K, Yamamoto T, et al. Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. J Biol Chem 2011;286(5):3992-4002
69. Le Stunff H, Coant N, Migrenne S, et al. Targeting lipid sensing in the central nervous system: new therapy against the development of obesity and type 2 diabetes. Expert Opin Ther Targets 2013;17(5):545-55
70. Martinez de Morentin PB, Varela L, Ferno J, et al. Hypothalamic lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2009;1801(3):350-61
71. Contreras C, Gonzalez-Garcia I, Martinez-Sanchez N, et al. Central ceramide-induced hypothalamic lipotoxicity and ER stress regulate energy balance. Cell Rep 2014;9(1):366-77
72. Zhang X, Zhang G, Zhang H, et al. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell 2008;135(1):61-73
73. Le Stunff H, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem 2004;92(5):882-99
74. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4(5):397-407
75. Aarthi JJ, Darendeliler MA, Pushparaj PN. Dissecting the role of the S1P/S1PR axis in health and disease. J Dent Res 2011;90(7):841-54
76. Mitra P, Oskeritzian CA, Payne SG, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 2006;103(44):16394-9
77. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator Biochim Biophys Acta 2002;1582(1-3):132-7
78. Rapizzi E, Taddei ML, Fiaschi T, et al. Sphingosine 1-phosphate increases glucose uptake through trans-activation of insulin receptor. Cell Mol Life Sci 2009;66(19):3207-18
79. Bruce CR, Risis S, Babb JR, et al. The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice. Endocrinology 2013;154(1):65-76
80. Bruce CR, Risis S, Babb JR, et al. Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice. Diabetes 2012;61(12):3148-55
81. Ma MM, Chen JL, Wang GG, et al. Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia 2007;50(4):891-900
82. Kendall MR, Hupfeld CJ. FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat diet-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice. Diabetes Obes Metab 2008;10(9):802-5
83. Qi Y, Chen J, Lay A, et al. Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic beta-cell death in diet-induced obese mice. FASEB J 2013;27(10):4294-304
84. Ross JS, Hu W, Rosen B, et al. Sphingosine kinase 1 is regulated by peroxisome proliferator-activated receptor alpha in response to free fatty acids and is essential for skeletal muscle interleukin-6 production and signaling in diet-induced obesity. J Biol Chem 2013;288(31):22193-206
85. Schuppel M, Kurschner U, Kleuser U, et al. Sphingosine 1-phosphate restrains insulin-mediated keratinocyte proliferation via inhibition of Akt through the S1P2 receptor subtype. J Invest Dermatol 2008;128(7):1747-56
86. Osawa Y, Seki E, Kodama Y, et al. Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMP-activated protein kinase suppression. FASEB J 2011;25(4):1133-44
87. Osawa Y, Uchinami H, Bielawski J, et al. Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J Biol Chem 2005;280(30):27879-87
88. Fayyaz S, Henkel J, Japtok L, et al. Involvement of sphingosine 1-phosphate in palmitate-induced insulin resistance of hepatocytes via the S1P2 receptor subtype. Diabetologia 2014;57(2):373-82
89. Laychock SG, Sessanna SM, Lin MH, et al. Sphingosine 1-phosphate affects cytokine-induced apoptosis in rat pancreatic islet beta-cells. Endocrinology 2006;147(10):4705-12
90. Veret J, Coant N, Gorshkova IA, et al. Role of palmitate-induced sphingoid base-1-phosphate biosynthesis in INS-1 beta-cell survival. Biochim Biophys Acta 2013;1831(2):251-62
91. Shimizu H, Okajima F, Kimura T, et al. Sphingosine 1-phosphate stimulates insulin secretion in HIT-T 15 cells and mouse islets. Endocr J 2000;47(3):261-9
92. Cantrell Stanford J, Morris AJ, Sunkara M, et al. Sphingosine 1-phosphate (S1P) regulates glucosestimulated insulin secretion in pancreatic beta cells. J Biol Chem 2012;287(16):13457-64
93. Samad F, Hester KD, Yang G, et al. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 2006;55(9):2579-87
94. Imasawa T, Koike K, Ishii I, et al. Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic beta-cells. Biochem Biophys Res Commun 2010;392(2):207-11
95. Levy M, Futerman AH. Mammalian ceramide synthases. IUBMB Life 2010;62(5):347-56
96. Wang J, Badeanlou L, Bielawski J, et al. Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance. Am J Physiol Endocrinol Metab 2014;306(7):E756-68
97. Sassa T, Ohno Y, Suzuki S, et al. Impaired epidermal permeability barrier in mice lacking elovl1, the gene responsible for very-long-chain fatty acid production. Mol Cell Biol 2013;33(14):2787-96
98. Jennemann R, Rabionet M, Gorgas K, et al. Loss of ceramide synthase 3 causes lethal skin barrier disruption. Hum Mol Genet 2011;21(3):586-608
99. Schulze H, Michel C, van Echten-Deckert G. Dihydroceramide desaturase. Methods Enzymol 2000;311:22-30
100. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007;5(3):167-79
101. Schiffmann S, Hartmann D, Fuchs S, et al. Inhibitors of specific ceramide synthases. Biochimie 2012;94(2):558-65
102. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011;17(1):55-63